Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. The company's management is set to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.
Investors and interested parties can access a live and archived webcast of the presentation through the 'Investors' section of the Pulmonx website. This conference provides an opportunity for Pulmonx to showcase its innovations and growth strategies in the field of lung disease treatments to a wider audience of investors and industry professionals.
Positive
- None.
Negative
- None.
News Market Reaction – LUNG
In the trading session that priced this news, LUNG gained 0.28%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.
A live and archived webcast of the presentation will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
